Clearer Standards Sought From FDA On Clinical Investigator Duties
This article was originally published in The Gray Sheet
Executive Summary
FDA held a public hearing April 23 to seek input on modernizing its clinical trials regulatory framework.
You may also be interested in...
HHS Drafts Proposal To Improve Human Research Regulations
Citing concerns over outdated regulations, HHS is recommending multi-site institutional review board reviews, updated informed-consent processes and revised risk calculations, among other changes, in a wide-reaching proposal to improve protections for human research subjects.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.